Lastly, quinazoline-based compounds such as EVP 4593, originally identified as Nuclear Factor kappa-light-chain-enhancer of activated B cells (NF-κB) inhibitor, have been recently recognized to target specifically CI [40] and to strongly suppress tumour growth in colon cancer xenografts in association with vascular endothelial growth factor (VEGF) inhibition [41]. The gene discussed is VEGFA; the disease is neoplasm.